Transiently achieved very low low-density lipoprotein cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: t... by Schwartz, Gregory G, Szarek, Michael, Bhatt, Deepak L, Bittner, Vera A, Bujas-Bobanovic, Maja, Diaz, Rafael, Fazio, Sergio, Fras, Zlatko, Goodman, Shaun G, Harrington, Robert A, Jukema, J Wouter, Manvelian, Garen, Pordy, Robert, Ray, Kausik K, Scemama, Michel, White, Harvey D, Steg, Ph Gabriel

Get full text

Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis by Sinnaeve, Peter R, Schwartz, Gregory G, Wojdyla, Daniel M, Alings, Marco, Bhatt, Deepak L, Bittner, Vera A, Chiang, Chern-En, Correa Flores, Roger M, Diaz, Rafael, Dorobantu, Maria, Goodman, Shaun G, Jukema, J Wouter, Kim, Yong-Un, Pordy, Robert, Roe, Matthew T, Sy, Rody G, Szarek, Michael, White, Harvey D, Zeiher, Andreas M, Steg, Ph Gabriel

Get full text

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial by Schwartz, Gregory G., MD, PhD, Bessac, Laurence, MD, Berdan, Lisa G., PA, MHS, Bhatt, Deepak L., MD, MPH, Bittner, Vera, MD, Diaz, Rafael, MD, Goodman, Shaun G., MD, MSc, Hanotin, Corinne, MD, Harrington, Robert A., MD, Jukema, J. Wouter, MD, PhD, Mahaffey, Kenneth W., MD, Moryusef, Angèle, MD, Pordy, Robert, MD, Roe, Matthew T., MD, MPH, Rorick, Tyrus, RN, Sasiela, William J., PhD, Shirodaria, Cheerag, MBBS, Szarek, Michael, PhD, Tamby, Jean-François, MD, Tricoci, Pierluigi, MD, White, Harvey, MBBS, DSc, Zeiher, Andreas, MD, Steg, Philippe Gabriel, MD

Get full text

Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OU... by Tuñón, José, Steg, Philippe Gabriel, Bhatt, Deepak L, Bittner, Vera A, Díaz, Rafael, Goodman, Shaun G, Jukema, J Wouter, Kim, Yong-Un, Li, Qian H, Mueller, Christian, Parkhomenko, Alexander, Pordy, Robert, Sritara, Piyamitr, Szarek, Michael, White, Harvey D, Zeiher, Andreas M, Schwartz, Gregory G

Get full text

Alirocumab after acute coronary syndrome in patients with a history of heart failure by White, Harvey D, Schwartz, Gregory G, Szarek, Michael, Bhatt, Deepak L, Bittner, Vera A, Chiang, Chern-En, Diaz, Rafael, Goodman, Shaun G, Jukema, Johan Wouter, Loy, Megan, Pagidipati, Neha, Pordy, Robert, Ristić, Arsen D, Zeiher, Andreas M, Wojdyla, Daniel M, Steg, Philippe Gabriel

Get full text

Response by Schwartz et al to Letter Regarding Article, “Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modifi... by Schwartz, Gregory G., Szarek, Michael, Bittner, Vera A., Steg, P. Gabriel

Get full text

Treatment of Heterozygous Familial Hypercholesterolemia in Children: Is Lower Better? by Bittner, Vera

Get full text

The Role of the Clinical Pharmacist in the Care of Patients With Cardiovascular Disease by Dunn, Steven P., PharmD, Birtcher, Kim K., MS, PharmD, Beavers, Craig J., PharmD, Baker, William L., PharmD, Brouse, Sara D., PharmD, Page, Robert L., PharmD, MSPH, Bittner, Vera, MD, MSPH, Walsh, Mary Norine, MD

Get full text

Impact of Female Sex on Lipid Lowering, Clinical Outcomes, and Adverse Effects in Atorvastatin Trials by Hsue, Priscilla Y., MD, Bittner, Vera A., MD, MSPH, Betteridge, John, MD, PhD, Fayyad, Rana, PhD, Laskey, Rachel, PhD, Wenger, Nanette K., MD, Waters, David D., MD

Get full text

Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests by Szarek, Michael, Reijnders, Esther, Jukema, J Wouter, Bhatt, Deepak L, Bittner, Vera A, Diaz, Rafael, Fazio, Sergio, Garon, Genevieve, Goodman, Shaun G, Harrington, Robert A, Ruhaak, L Renee, Schwertfeger, Markus, Tsimikas, Sotirios, White, Harvey D, Steg, P Gabriel, Cobbaert, Christa, Schwartz, Gregory G

Get full text

Analysis of vitamin D levels in patients with and without statin-associated myalgia — A systematic review and meta-analysis of 7 studies with 2420 patients by Michalska-Kasiczak, Marta, Sahebkar, Amirhossein, Mikhailidis, Dimitri P, Rysz, Jacek, Muntner, Paul, Toth, Peter P, Jones, Steven R, Rizzo, Manfredi, Kees Hovingh, G, Farnier, Michel, Moriarty, Patrick M, Bittner, Vera A, Lip, Gregory Y.H, Banach, Maciej

Get full text

Underutilization of High-Intensity Statin Therapy After Hospitalization for Coronary Heart Disease by Rosenson, Robert S., MD, Kent, Shia T., PhD, Brown, Todd M., MD, Farkouh, Michael E., MD, Levitan, Emily B., PhD, Yun, Huifeng, MD, PhD, Sharma, Pradeep, MS, Safford, Monika M., MD, Kilgore, Meredith, PhD, Muntner, Paul, PhD, Bittner, Vera, MD

Get full text

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial by White, Harvey D, Steg, Ph Gabriel, Szarek, Michael, Bhatt, Deepak L, Bittner, Vera A, Diaz, Rafael, Edelberg, Jay M, Erglis, Andrejs, Goodman, Shaun G, Hanotin, Corinne, Harrington, Robert A, Jukema, J Wouter, Lopes, Renato D, Mahaffey, Kenneth W, Moryusef, Angele, Pordy, Robert, Roe, Matthew T, Sritara, Piyamitr, Tricoci, Pierluigi, Zeiher, Andreas M, Schwartz, Gregory G

Get full text

Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research Wit... by Virani, Salim S, Akeroyd, Julia M, Nambi, Vijay, Heidenreich, Paul A, Morris, Pamela B, Nasir, Khurram, Michos, Erin D, Bittner, Vera A, Petersen, Laura A, Ballantyne, Christie M

Get full text

Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES Trial by Goodman, Shaun G, Steg, Philippe Gabriel, Poulouin, Yann, Bhatt, Deepak L, Bittner, Vera A, Diaz, Rafael, Garon, Genevieve, Harrington, Robert A, Jukema, J Wouter, Manvelian, Garen, Stipek, Wanda, Szarek, Michael, White, Harvey D, Schwartz, Gregory G

Get full text

Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial by Bhatt, Deepak L, Briggs, Andrew H, Reed, Shelby D, Annemans, Lieven, Szarek, Michael, Bittner, Vera A, Diaz, Rafael, Goodman, Shaun G, Harrington, Robert A, Higuchi, Keiko, Joulain, Florence, Jukema, J Wouter, Li, Qian H, Mahaffey, Kenneth W, Sanchez, Robert J, Roe, Matthew T, Lopes, Renato D, White, Harvey D, Zeiher, Andreas M, Schwartz, Gregory G, Gabriel Steg, Ph

Get full text

Association of Serum Lipids and Coronary Heart Disease in Contemporary Observational Studies by Colantonio, Lisandro D, Bittner, Vera, Reynolds, Kristi, Levitan, Emily B, Rosenson, Robert S, Banach, Maciej, Kent, Shia T, Derose, Stephen F, Zhou, Hui, Safford, Monika M, Muntner, Paul

Get full text

Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial by Diaz, Rafael, Li, Qian H, Bhatt, Deepak L, Bittner, Vera A, Baccara-Dinet, Marie T, Goodman, Shaun G, Jukema, J Wouter, Kimura, Takeshi, Parkhomenko, Alexander, Pordy, Robert, Reiner, Željko, Roe, Matthew T, Szarek, Michael, Tse, Hung-Fat, White, Harvey D, Zahger, Doron, Zeiher, Andreas M, Schwartz, Gregory G, Steg, Ph Gabriel

Get full text

Impact of Chronic Kidney Disease on Outcomes of Myocardial Revascularization in Patients With Diabetes by Farkouh, Michael E., Sidhu, Mandeep S., Brooks, Maria M., Vlachos, Helen, Boden, William E., Frye, Robert L., Hartigan, Pamela, Siami, F.S., Bittner, Vera A., Chaitman, Bernard R., Mancini, G.B. John, Fuster, Valentin

Get full text

Treatment Thresholds and ASCVD Risk by Bittner, Vera

Get full text